Phenotype Guided Vasoactive Medication During Kidney Transplantation
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorJennifer Cutler
About this trial
The goal of this clinical trial is to learn if vasopressin improves the body's response to intravenous fluids during kidney transplantation in patients who have relaxed blood vessels. Researchers will compare the results of vasopressin to those who received calcium chloride.
Eligibility criteria
Qualifiers
Adults aged 18 years or older
Undergoing kidney transplantation at Cedars-Sinai Medical Center
Able to provide informed consent
Disqualifiers
Patients unable to provide informed consent
Patients with contraindications to protocol vasoactive medications, as determined by the treating anesthesiologist
Patients in whom required intraoperative monitoring cannot be performed
Trial design
Treatments tested in this trial
- Phenotype-Guided Vasoactive Management
Treatment groups
255 Participants
are divided into 1 treatment groupSponsors and collaborators
Jennifer Cutler
Lead sponsor
Cedars-Sinai Medical Center
Sponsor institution
Source ClinicalTrials.gov